Scilex Bio says KDS201 currently enrolling with U.S. patient cohort to be added

Scilex (SCLX) Bio, a controlling interest of joint venture by Scilex Holding Company with IPMC Company, a representative company of the Bio Innovation Consortium which holds the exclusive rights to NeuroBiogen Company’s KDS2010 global license, announced that KDS2010 is a new reversible selective monoamine oxidase B inhibitor being studied for its potential in treating neurodegenerative diseases like Alzheimer’s disease. KDS2010 pharmacokinetics, lack of food effect, safety and dose selection have been characterized in Single Ascending Dose and Multiple Ascending Dose Phase 1 clinical trials with 88 healthy young adults and elderly subjects and between Korean and Western populations, demonstrating favorable safety and tolerability and adequate pharmacokinetics for once-daily dosing. A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of KDS2010 in Patients with Alzheimer’s Disease with Mild Cognitive Impairment and Mild Dementia is currently recruiting in South Korea in 114 patients and U.S. cohort will be added in 2025.